Atypical antipsychotic combined with androgen deprivation therapy

This page covers all Atypical antipsychotic combined with androgen deprivation therapy drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Dopamine D2/D3 receptors (aripiprazole component); androgen receptor (ADT component).

Targets

Dopamine D2/D3 receptors (aripiprazole component); androgen receptor (ADT component)

Phase 3 pipeline (1)

• Aripiprazole+ ADT · Otsuka Pharmaceutical Development & Commercialization, Inc. · Psychiatry / Oncology
  Aripiprazole is a dopamine D2/D3 receptor partial agonist combined with an androgen deprivation therapy (ADT) agent to treat psychiatric symptoms in patients undergoing hormone therapy.

Patent intelligence

• atypical antipsychotic combined with androgen deprivation therapy patent landscape — aggregated cliff calendar, attackable patents, originator estates